NCT04282200

Ketorolac in Acute Pancreatitis

The Use of Intravenous Ketorolac in a Multimodal Approach to Pain Management in Acute Pancreatitis

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: University of Cincinnati · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study will compare pain management strategies for patients hospitalized with acute pancreatitis. Standard of care pain management will be compared to standard of care plus intravenous ketorolac.

Detailed description

Patients hospitalized for acute pancreatitis and admitted to an internal medicine team will be eligible for study. Patients enrolled will be blindly randomized to receive open-label pain management of standard of care or standard of care plus intravenous ketorolac. Patients will be enrolled between hour 24 and 48 of hospitalization.

Conditions

• Acute Pancreatitis

Interventions

Type	Name	Description
DRUG	Ketorolac	intravenous ketorolac 30 mg every 6 hours

Timeline

• Start date: 2020-02-24
• Primary completion: 2021-12-01
• Completion: 2022-12-01
• First posted: 2020-02-24
• Last updated: 2020-12-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study